Automated Quantitative Assessment of HER-2/neu Immunohistochemical Expression in Breast Cancer

The expression of the HER-2/neu (HER2) gene, a member of the epidermal growth factor receptor family, has been shown to be a valuable prognostic indicator for breast cancer. However, interobserver variability has been reported in the evaluation of HER2 with immunohistochemistry. It has been suggested that automated computer-based evaluation can provide a consistent and objective evaluation of HER2 expression. In this manuscript, we present an automated method for the quantitative assessment of HER2 using digital microscopy. The method processes microscopy images from tissue slides with a multistage algorithm, including steps of color pixel classification, nuclei segmentation, and cell membrane modeling, and extracts quantitative, continuous measures of cell membrane staining intensity and completeness. A minimum cluster distance classifier merges the features to classify the slides into HER2 categories. An evaluation based on agreement analysis with pathologist-derived HER2 scores, showed good agreement with the provided truth. Agreement varied within the different classes with highest agreement (up to 90%) for positive (3+) slides, and lowest agreement (72%-78%) for equivocal (2+) slides which contained ambiguous scoring. The developed automated method has the potential to be used as a computer aid for the immunohistochemical evaluation of HER2 expression with the objective of increasing observer reproducibility.

[1]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[2]  Hiroko Yamashita,et al.  Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer , 2003, Breast Cancer Research.

[3]  Greg Yothers,et al.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.

[4]  K A Matkowskyj,et al.  Quantitative Immunohistochemistry by Measuring Cumulative Signal Strength Using Commercially Available Software Photoshop and Matlab , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[5]  S J Schnitt,et al.  Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  John R. Mackey,et al.  Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. , 2009 .

[8]  Min C. Shin,et al.  Does colorspace transformation make any difference on skin detection? , 2002, Sixth IEEE Workshop on Applications of Computer Vision, 2002. (WACV 2002). Proceedings..

[9]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[10]  Hung Chiang,et al.  Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. , 2002, American journal of clinical pathology.

[11]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[12]  Nandini Dendukuri,et al.  Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis , 2007, Canadian Medical Association Journal.

[13]  E. Frenkel,et al.  Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. , 2001, American journal of clinical pathology.

[14]  Oliver Hoffmann,et al.  Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases , 2004, Modern Pathology.

[15]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[16]  K I Bland,et al.  Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53 , 2001, Annals of surgery.

[17]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[18]  Stephen M Hewitt,et al.  Perspectives in tissue microarrays. , 2004, Combinatorial chemistry & high throughput screening.

[19]  K. Shen,et al.  Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .

[20]  H A Lehr,et al.  Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. , 2001, American journal of clinical pathology.

[21]  Pierre Soille,et al.  Morphological Image Analysis: Principles and Applications , 2003 .

[22]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Larry Norton,et al.  HER2 and response to paclitaxel in node-positive breast cancer. , 2007, The New England journal of medicine.

[24]  D. Rimm,et al.  Immunohistochemistry and quantitative analysis of protein expression. , 2009, Archives of pathology & laboratory medicine.

[25]  T. Seidal,et al.  Interpretation and Quantification of Immunostains , 2001, The American journal of surgical pathology.

[26]  Holly Dressman,et al.  Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. , 2003, Human molecular genetics.

[27]  G. Oberhuber,et al.  Is fluorescence in situ hybridization really superior to HercepTest? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C Sotiriou,et al.  Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  David L Rimm,et al.  Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. , 2003, Cancer research.

[30]  Danila Coradini,et al.  Biomolecular prognostic factors in breast cancer , 2004, Current opinion in obstetrics & gynecology.

[31]  B. Everitt,et al.  Statistical methods for rates and proportions , 1973 .

[32]  A. Thor,et al.  Histopathologic Characteristics Predicting HER-2/neu Amplification in Breast Cancer , 2007 .

[33]  Jinha M. Park,et al.  Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials , 2005, Clinical Cancer Research.

[34]  Andrew W. Fitzgibbon,et al.  Direct Least Square Fitting of Ellipses , 1999, IEEE Trans. Pattern Anal. Mach. Intell..

[35]  R. Gelber,et al.  Polychemotherapy for early breast cancer , 2001, The Lancet.

[36]  Robert D Cardiff,et al.  Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. , 2004, Cancer research.

[37]  I Vergote,et al.  A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. , 1997, Journal of clinical pathology.

[38]  O. Kallioniemi,et al.  Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and dna flow cytometry , 1990, Cancer.

[39]  Stephen M Hewitt,et al.  Tissue microarrays: bridging the gap between research and the clinic , 2005, Expert review of proteomics.

[40]  Anne Kallioniemi,et al.  Molecular signatures of breast cancer--predicting the future. , 2002, The New England journal of medicine.

[41]  H. Kundel,et al.  Measurement of observer agreement. , 2003, Radiology.

[42]  J. Fletcher,et al.  HER-2/neu (c-erb-B2) gene and protein in breast cancer. , 1999, American journal of clinical pathology.

[43]  Hubert Cardot,et al.  Cooperation of color pixel classification schemes and color watershed: a study for microscopic images , 2002, IEEE Trans. Image Process..

[44]  Lajos Pusztai,et al.  Breast cancer biomarkers and molecular medicine , 2003, Expert review of molecular diagnostics.

[45]  S. Bose,et al.  The Akt pathway in human breast cancer: a tissue-array-based analysis , 2006, Modern Pathology.

[46]  Andrew S. Glassner,et al.  Principles of Digital Image Synthesis , 1995 .

[47]  Ioannis Pitas,et al.  Automated evaluation of her-2/neu status in breast tissue from fluorescent in situ hybridization images , 2005, IEEE Transactions on Image Processing.

[48]  O. Stål,et al.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.

[49]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[50]  Greg Yothers,et al.  Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J. Bartlett,et al.  The clinical evaluation of HER‐2 status: which test to use? , 2003, The Journal of pathology.

[52]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[53]  S Toikkanen,et al.  Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  John J Spinelli,et al.  HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.

[55]  Hubert Cardot,et al.  Bayesian marker extraction for color watershed in segmenting microscopic images , 2002, Object recognition supported by user interaction for service robots.

[56]  Cornelius Diamond,et al.  A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  Lajos Pusztai,et al.  Breast cancer biomarkers and molecular medicine: part II , 2004, Expert review of molecular diagnostics.

[58]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  R. F. Wagner,et al.  Assessment of medical imaging systems and computer aids: a tutorial review. , 2007, Academic radiology.

[60]  A. Gown,et al.  Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? , 2004, Human pathology.

[61]  K. Edmiston,et al.  HER-2 Status in Breast Cancer: Correlation of Gene Amplification by FISH With Immunohistochemistry Expression Using Advanced Cellular Imaging System , 2006, Applied immunohistochemistry & molecular morphology : AIMM.

[62]  H. Tsuda,et al.  Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTestTM in breast carcinoma by image analysis , 2001, Pathology international.

[63]  Abdesselam Bouzerdoum,et al.  Skin segmentation using color pixel classification: analysis and comparison , 2005, IEEE Transactions on Pattern Analysis and Machine Intelligence.